AKT1 and neoplasm: In conclusion, ponatinib exhibits anti-tumor efficacy in NB by inhibiting FGFR1 signaling and blocking the activation of PI3K/AKT/mTOR and JAK/STAT3 signaling pathways, as evidenced by both in vitro and in vivo assays.